Glenmark Pharmaceuticals proposes INR 2.50 dividend for Glenmark Pharmaceuticals stock

Published on 10/02/2026 at 22:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Glenmark proposed INR 2.50 per share for fiscal 2026 on September 11, 2026. Motilal Oswal kept its INR 2,570 target for Glenmark Pharmaceuticals stock.

Glenmark, INE935A01035, Illustration mit AI erstellt.

Glenmark Pharmaceuticals proposed a dividend of INR 2.50 per equity share for fiscal 2026 at its annual meeting on September 11, 2026, according to MarketScreener. The payout decision adds a shareholder-return angle to a business picture led by strong first-quarter growth.

Dividend proposal sets the tone

The proposed dividend applies to the year ended March 31, 2026, and was presented at Glenmark Pharmaceuticals' 48th annual general meeting. The INR 2.50 amount gives the stock a concrete capital-return reference alongside its research and product pipeline.

The company operates across branded and generic medicines, with key therapeutic areas including respiratory care, dermatology and oncology. Its international footprint spans India, North America, Latin America and Europe.

Analyst target stays above market

DSIJ reported on August 3, 2026, that Motilal Oswal Financial Services retained a Buy recommendation and an INR 2,570 target after the first-quarter update. The broker cited India and North America launches, respiratory products and pipeline commercialization as growth drivers.

The same research update also flagged higher raw-material, freight, research and development, and marketing costs. It said management maintained fiscal 2027 EBITDA margin guidance of 21 percent to 22 percent, while research and development investment was expected at 7 percent to 8 percent of sales.

First-quarter growth brings a comparison

For the first quarter of fiscal 2027, Glenmark reported revenue of INR 4.0185 billion, up 23.10 percent year on year, while EBITDA rose 38.60 percent to INR 804.8 crore, according to DSIJ. Profit after tax increased 53.80 percent to INR 480 crore, although the broker said the figure was 10 percent below its estimate.

The operating picture therefore has two distinct elements. Revenue and profit grew sharply from the year-earlier base, while the analyst update points to cost pressure and a need for continued execution in the United States and India.

Stock closes below its yearly high

On NSE India, Glenmark closed at INR 2,331.00 on October 1, 2026, down 0.16 percent from the prior close of INR 2,334.70. Its 52-week range was INR 1,792.60 to INR 2,537.60, while market capitalization stood at INR 657.8 billion as of October 1, 2026.